NCT03348982

Brief Summary

This study aims to investigate whether physical activity intervention would be effective to improve sleep quality in children with ASD, and investigate how physical activity impacts on sleep in children with ASD through melatonin-mediated mechanism model. A parallel-group randomized controlled trial comparing a 12-week jogging intervention and a control group receiving standard care in 32 children with ASD will be conducted. This study will monitor the changes of four sleep parameters (sleep onset latency; sleep efficiency, wake after sleep onset and sleep duration) through objective actigraphic assessment and parental sleep logs.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2018

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 21, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2019

Completed
Last Updated

December 6, 2017

Status Verified

November 1, 2017

Enrollment Period

1.4 years

First QC Date

November 9, 2017

Last Update Submit

December 5, 2017

Conditions

Keywords

Physical activitySleepChildrenAutism Spectrum DisorderMelatonin

Outcome Measures

Primary Outcomes (6)

  • Sleep onset latency

    Sleep onset latency (length of time taken to fall asleep, expressed in minutes, SOL) will be objectively measured by a GT3X accelerometer.

    12-week

  • Sleep efficiency

    Sleep efficiency (actual sleep time divided by time in bed, expressed as a percent, SE) will be objectively measured by a GT3X accelerometer.

    12-week

  • Wake after sleep onset

    Wake after sleep onset (length of time they were awake after sleep onset, expressed in minutes, WASO) will be objectively measured by a GT3X accelerometer.

    12-week

  • Sleep duration

    sleep duration (total sleep in hours and minutes, SD) will be objectively measured by a GT3X accelerometer.

    12-week

  • Parental-assessed sleep quality

    Participants' sleep patterns will be logged by their parents using Children's Sleep Habits Questionnaire (CSHQ), which is a validated 45-item parent-administered questionnaire to examine sleep patterns of young children. The total score ranged from 45 to 135.

    12-week

  • Melatonin

    All participants will be instructed to collect a 24-h urine sample. 6-sulfatoxymelatonin, a creatinine-adjusted morning urinary melatonin and representative of melatonin level, will be measured from the sample. The weekend has been chosen to allow the participants to stay at home for sample collection. All urine samples will be collected using 24-h urine bottles containing 0.1L of 0.5M hydrochloric acid as a preservative.

    12-week

Study Arms (2)

Intervention group

EXPERIMENTAL

The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.

Behavioral: Jogging program

Control group

NO INTERVENTION

Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).

Interventions

Jogging programBEHAVIORAL

The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).

Intervention group

Eligibility Criteria

Age9 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • pre-puberty or early puberty as indicated by Tanner stage I or II ;
  • ASD diagnosis from a physician based on Diagnostic and Statistical Manual of Mental Disorders, 5th edition, (DSM-V)\[42\]
  • non-verbal IQ over 40
  • the ability to follow instructions;
  • physically able to participate in the intervention
  • no additional regular participation in physical exercise other than school physical education classes for at least 6 months prior to the study
  • no concurrent medication for at least 6 months before the study or any prior melatonin treatment;
  • have sleep difficulties, including sleep onset insomnia and frequent and prolonged nightwaking and/or early morning awakenings reported by parents

You may not qualify if:

  • with one or co-morbid psychiatric disorders as established by a structured interview based on DSM-V
  • with other medical conditions that limit their physical activity capacities (e.g., asthma, seizure, cardiac disease);
  • with a complex neurologic disorder (e.g., epilepsy, phenylketonuria, fragile X syndrome, tuberous sclerosis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Tse ACY, Lee PH, Zhang J, Lai EWH. Study protocol for a randomised controlled trial examining the association between physical activity and sleep quality in children with autism spectrum disorder based on the melatonin-mediated mechanism model. BMJ Open. 2018 Apr 13;8(4):e020944. doi: 10.1136/bmjopen-2017-020944.

MeSH Terms

Conditions

Motor ActivitySleep Apnea SyndromesAutism Spectrum Disorder

Condition Hierarchy (Ancestors)

BehaviorApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesChild Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Central Study Contacts

Andy CY Tse, PhD

CONTACT

Paul H Lee, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 9, 2017

First Posted

November 21, 2017

Study Start

January 1, 2018

Primary Completion

June 1, 2019

Study Completion

June 1, 2019

Last Updated

December 6, 2017

Record last verified: 2017-11